| Identification | Back Directory | [Name]
MA-0204 | [CAS]
2095128-17-7 | [Synonyms]
MA-0204
CS-2841
Hexanoic acid, 3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-1H-imidazol-1-yl]methyl]phenoxy]-, (3R)- | [Molecular Formula]
C25H27F3N2O4 | [MDL Number]
MFCD31807611 | [MOL File]
2095128-17-7.mol | [Molecular Weight]
476.49 |
| Chemical Properties | Back Directory | [Boiling point ]
611.9±65.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
4.76±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC50s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD)[1]. | [in vivo]
PPARδ (30, 100 mg/kg) increases target gene transcription in the muscle[1]. | [IC 50]
PPARδ: 0.4 nM (EC50, in human); PPARδ: 7.9 nM (EC50, in mouse); PPARδ: 10 nM (EC50, in rat) | [References]
[1] Lagu B, et al. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett. 2018 Jul 31;9(9):935-940. DOI:10.1021/acsmedchemlett.8b00287 |
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|